Lisata Therapeutics, Inc. - Common Stock (LSTA)
1.1200
-0.0200 (-1.75%)
NASDAQ· Last Trade: Aug 5th, 5:29 PM EDT
These stocks are moving in today's after hours sessionchartmill.com
Via Chartmill · July 28, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · July 21, 2026
The market is filled with gapping stocks in Tuesday's session.chartmill.com
Via Chartmill · July 21, 2026
Wondering what's happening in today's pre-market session?chartmill.com
Via Chartmill · July 21, 2026
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics (NASDAQ:LSTA)
Via Benzinga · July 9, 2026
In today's session, these stocks are experiencing unusual volume.chartmill.com
Via Chartmill · January 27, 2026
The trading volume of these stocks is deviating from the norm in today's session.chartmill.com
Via Chartmill · January 22, 2026
Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.
Via Stocktwits · January 21, 2026
Lisata Therapeutics reported a narrower-than-expected Q3 2025 loss, advancing its lead candidate, certepetide, with a cash runway into 2027.
Via Chartmill · November 6, 2025
Via Benzinga · November 4, 2025
Via Benzinga · July 21, 2025

Via Benzinga · January 22, 2025

Via Benzinga · January 22, 2025

Via Benzinga · January 22, 2025

Via Benzinga · January 22, 2025

LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024

Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing on detecting circulating tumor DNA.
Via Benzinga · July 18, 2024

Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Via News Direct · May 13, 2024


